In Episode 4 of the podcast series from the GTEC on T cells and vaccine efficacy, Helen Fletcher, Professor of Immunology at the London School of Hygiene & Tropical Medicine, and Katie Flanagan, Professor of Vaccinology and Immunology and Director of Infectious Diseases for the North and Northwest of Tasmania, discuss vaccine efficacy in different patient demographics. 

Prof. Fletcher and Prof. Flanagan discuss how study populations are selected for clinical trials and how real-world patient populations may differ from those evaluated in randomised clinical trials. They also address how vaccine efficacy may be affected by differences in patient characteristics between clinical trials and real-world clinical practice and what role T cells may have in evaluating efficacy in different patient populations.

This podcast was developed by the Global T cell Expert Consortium (GTEC), an initiative set up to bring together experts in T cells, vaccines, immunology and public health worldwide, with the aim of becoming the leading voice in T cell research during and beyond the current COVID-19 pandemic. The GTEC will educate on T cells and vaccine development through the release of publicly available educational content, and foster collaborative research efforts to address the unmet needs and unanswered questions in T cell research and vaccinology. This initiative is sponsored by Oxford Immunotec.

The COVID-19 pandemic is a rapidly changing situation: the content of this podcast was correct at time of recording in April 2021.